Diagnostic performance of MRI in detecting prostate cancer in patients with prostate-specific antigen levels of 4–10 ng/mL: a systematic review and meta-analysis

Autor: Erjia Guo, Lili Xu, Daming Zhang, Jiahui Zhang, Xiaoxiao Zhang, Xin Bai, Li Chen, Qianyu Peng, Gumuyang Zhang, Zhengyu Jin, Hao Sun
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Insights into Imaging, Vol 15, Iss 1, Pp 1-12 (2024)
Druh dokumentu: article
ISSN: 1869-4101
DOI: 10.1186/s13244-024-01699-4
Popis: Abstract Objective To investigate the diagnostic performance of MRI in detecting clinically significant prostate cancer (csPCa) and prostate cancer (PCa) in patients with prostate-specific antigen (PSA) levels of 4–10 ng/mL. Methods A computerized search of PubMed, Embase, Cochrane Library, Medline, and Web of Science was conducted from inception until October 31, 2023. We included articles on the use of MRI to detect csPCa or PCa at 4–10 ng/mL PSA. The primary and secondary outcomes were MRI performance in csPCa and PCa detection, respectively; the estimates of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were pooled in a bivariate random-effects model. Results Among the 19 studies (3879 patients), there were 10 (2205 patients) and 13 studies (2965 patients) that reported MRI for detecting csPCa or PCa, respectively. The pooled sensitivity and specificity for csPCa detection were 0.84 (95% confidence interval [CI], 0.79–0.88) and 0.76 (95%CI, 0.65–0.84), respectively, for PCa detection were 0.82 (95%CI, 0.75–0.87) and 0.74 (95%CI, 0.65–0.82), respectively. The pooled NPV for csPCa detection was 0.91 (0.87–0.93). Biparametric magnetic resonance imaging also showed a significantly higher sensitivity and specificity relative to multiparametric magnetic resonance imaging (both p
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje